MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

Extensive-stage Small-cell Lung Cancer Clinical Trial

— MGC018-SCLC  

Official title:

A Phase II Study of MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06227546
• Other study ID #: STUDY00007316
• Status: Recruiting
• Phase: Phase 2
• Start date: April 15, 2024
• Est. completion date: May 2026

Study information

• Verified date: April 2024
• Source: Georgetown University
• Contact: Chul Kim, MD
• Phone: 202-444-2223
• Email: Chul.Kim[@]gunet.georgetown.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to test MGC018 in patients with relapsed or refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). The main question it aims to answer is:

• Does the administration of MGC018 achieve a clinically meaningful response rate of 25% in patients with relapsed or refractory ES-SCLC?

Participants enrolled in the trial will receive MGC018 through an intravenous (IV) infusion, every 28 days until disease progression or unacceptable toxicity. Tumor assessment will be done every 2 cycles (28 day cycles). Blood samples will be taken for biomarker analysis before treatment, on cycle 3 day 1, and at progression. A pretreatment biopsies will be done.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 17
• Est. completion date: May 2026
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age greater than or equal to 18 years at time of signing Informed consent form (ICF)

2. Ability to comply with the study protocol, in the investigator's judgment.

3. Histologically or cytologically confirmed advanced small cell lung cancer that is not amenable to definitive therapy. Patients with epidermal growth factor receptor (EGFR)-mutant Non Small Cell Lung Cancer (NSCLC) that has transformed to Small Cell Lung Cancer (SCLC) will be allowed if their SCLC has progressed following treatment with platinum-based chemotherapy.

4. Disease progression during or following treatment with platinum-based chemotherapy.

a) Patients could have received any number of therapies for relapsed or progressive disease.

5. Measurable disease per RECIST v1.1

6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2

7. Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment:

1. Absolute Neutrophil Count (ANC) greater than or equal to (>/=) 1.0 x 10^9/L (1000/uL) without granulocyte colony-stimulating factor support

2. Platelet count >/=100 x 10^9/L (100,000/uL) without transfusion

3. Hemoglobin >/= 80 g/L (8 g/dL) (1) Patients may be transfused to meet this criterion.

4. Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and alkaline phosphatase (ALP) less than or equal to (</=) 2.5 x upper limit of normal (ULN), with the following exceptions:

1. Patients with documented liver metastases: AST and ALT </= 5 x ULN

2. Patients with documented liver or bone metastases: ALP </= 5 x ULN

5. Serum bilirubin </= 1.5 x ULN with the following exception:

(1) Patients with known Gilbert disease: serum bilirubin </= 3 x ULN

6. Creatinine clearance >/= 30 mL/min (calculated using the Cockcroft-Gault formula)

7. For patients not receiving therapeutic anticoagulation: international normalized ratio (INR) and Partial Thromboplastin Time, Activated (aPTT) </= 1.5 x ULN

8. Ability to understand and the willingness to sign a written informed consent document.

9. Availability of pre-treatment tumor tissue via a fresh biopsy. If biopsy is not considered safe and medically feasible by the Investigator, the patient may be approved for enrollment after consultation with the Principal Investigator.

10. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs, as defined below:

1. Women must remain abstinent or use contraceptive methods with a failure rate of less than (<) 1% per year during the treatment period and for 6 months after the final dose of study treatment. Women must refrain from donating eggs during this same period.

2. A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state ( >/= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.

3. Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.

4. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.

11. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:

1. With a female partner of childbearing potential who is not pregnant, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 90 days after the final dose of MGC018. Men must refrain from donating sperm during this this same period.

2. With a pregnant female partner, men must remain abstinent or use a condom during the treatment period and 90 days after the final dose of MGC018 to avoid potential exposure to the embryo.

3. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.

Exclusion Criteria:

1. Patients with treated brain metastases are eligible if they are symptomatically stable while off steroid therapy for a minimum of 7 days

2. History of leptomeningeal disease

3. Patient who are receiving any other investigational agents

4. Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study

5. Diagnosis of another malignancy. However, patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

6. Evidence of pleural and/or pericardial effusion. A small and/or asymptomatic effusion is not exclusionary.

7. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the view of the investigator, contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.

8. Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 6 months after the final dose of study treatment.

Related Conditions & MeSH terms

• Extensive-stage Small-cell Lung Cancer
• Lung Neoplasms
• Small Cell Lung Carcinoma

Intervention

Drug:
• MGC018
Intravenous (IV) Infusion, 2.7 mg/kg on Day 1 of each 28 day cycle

Locations

Country	Name	City	State
United States	The Harry and Jeanette Weinberg Cancer Institute at MedStar Franklin Square Medical Center	Baltimore	Maryland
United States	Hackensack Meridian Health, John Theurer Cancer Center	Hackensack	New Jersey
United States	Lombardi Comprehensive Cancer Center, Georgetown University	Washington	District of Columbia
United States	Medstar Washington Hospital Center	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Georgetown University	MacroGenics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)	Investigator-Assessed ORR as determined by RECIST v1.1 with tumor imaging assessments obtained every 2 cycles (each cycle is a 28 day cycle).	1 year
Secondary	Incidence of Adverse Events	Number of participants with Investigator assessed treatment emergent adverse events per Common terminology criteria for adverse effects (CTCAE) version 5.0	from start of treatment through 60 days after last treatment, approximately 1 year
Secondary	Duration of response (DOR)	Defined as the time from response to disease progression or death in patients who achieve complete or partial response.	1 year
Secondary	Progression-free survival (PFS) Median	Defined as the time from study drug initiation until progression event or death as assessed using the Kaplan-Meier method.	1 year
Secondary	Progression-free survival (PFS) 6 months	Defined as the time from study drug initiation until progression event or death as assessed using the Kaplan-Meier method.	6 months
Secondary	Overall Survival (OS)	Defined as time from study drug initiation to death as assessed using the Kaplan-Meier method.	3 years